Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome
Copyright © 2020 The Authors, some rights reserved. Fragile X syndrome is caused by FMR1 gene silencing and loss of the encoded fragile X mental retardation protein (FMRP), which binds to mRNA and regulates translation. Studies in the Fmr1-/y mouse model of fragile X syndrome indicate that aberrant...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association for the Advancement of Science (AAAS)
2021
|
| Online Access: | https://hdl.handle.net/1721.1/138160 |
| _version_ | 1826205317541658624 |
|---|---|
| author | McCamphill, Patrick K Stoppel, Laura J Senter, Rebecca K Lewis, Michael C Heynen, Arnold J Stoppel, David C Sridhar, Vinay Collins, Katie A Shi, Xi Pan, Jen Q Madison, Jon Cottrell, Jeffrey R Huber, Kimberly M Scolnick, Edward M Holson, Edward B Wagner, Florence F Bear, Mark F |
| author_facet | McCamphill, Patrick K Stoppel, Laura J Senter, Rebecca K Lewis, Michael C Heynen, Arnold J Stoppel, David C Sridhar, Vinay Collins, Katie A Shi, Xi Pan, Jen Q Madison, Jon Cottrell, Jeffrey R Huber, Kimberly M Scolnick, Edward M Holson, Edward B Wagner, Florence F Bear, Mark F |
| author_sort | McCamphill, Patrick K |
| collection | MIT |
| description | Copyright © 2020 The Authors, some rights reserved. Fragile X syndrome is caused by FMR1 gene silencing and loss of the encoded fragile X mental retardation protein (FMRP), which binds to mRNA and regulates translation. Studies in the Fmr1-/y mouse model of fragile X syndrome indicate that aberrant cerebral protein synthesis downstream of metabotropic glutamate receptor 5 (mGluR5) signaling contributes to disease pathogenesis, but clinical trials using mGluR5 inhibitors were not successful. Animal studies suggested that treatment with lithium might be an alternative approach. Targets of lithium include paralogs of glycogen synthase kinase 3 (GSK3), and nonselective small-molecule inhibitors of these enzymes improved disease phenotypes in a fragile X syndrome mouse model. However, the potential therapeutic use of GSK3 inhibitors has been hampered by toxicity arising from inhibition of both α and β paralogs. Recently, we developed GSK3 inhibitors with sufficient paralog selectivity to avoid a known toxic consequence of dual inhibition, that is, increased β-catenin stabilization. We show here that inhibition of GSK3α, but not GSK3β, corrected aberrant protein synthesis, audiogenic seizures, and sensory cortex hyperexcitability in Fmr1-/y mice. Although inhibiting either paralog prevented induction of NMDA receptor–dependent long-term depression (LTD) in the hippocampus, only inhibition of GSK3α impaired mGluR5-dependent and protein synthesis–dependent LTD. Inhibition of GSK3α additionally corrected deficits in learning and memory in Fmr1-/y mice; unlike mGluR5 inhibitors, there was no evidence of tachyphylaxis or enhanced psychotomimetic-induced hyperlocomotion. GSK3α selective inhibitors may have potential as a therapeutic approach for treating fragile X syndrome. |
| first_indexed | 2024-09-23T13:11:07Z |
| format | Article |
| id | mit-1721.1/138160 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T13:11:07Z |
| publishDate | 2021 |
| publisher | American Association for the Advancement of Science (AAAS) |
| record_format | dspace |
| spelling | mit-1721.1/1381602021-11-20T03:17:53Z Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome McCamphill, Patrick K Stoppel, Laura J Senter, Rebecca K Lewis, Michael C Heynen, Arnold J Stoppel, David C Sridhar, Vinay Collins, Katie A Shi, Xi Pan, Jen Q Madison, Jon Cottrell, Jeffrey R Huber, Kimberly M Scolnick, Edward M Holson, Edward B Wagner, Florence F Bear, Mark F Copyright © 2020 The Authors, some rights reserved. Fragile X syndrome is caused by FMR1 gene silencing and loss of the encoded fragile X mental retardation protein (FMRP), which binds to mRNA and regulates translation. Studies in the Fmr1-/y mouse model of fragile X syndrome indicate that aberrant cerebral protein synthesis downstream of metabotropic glutamate receptor 5 (mGluR5) signaling contributes to disease pathogenesis, but clinical trials using mGluR5 inhibitors were not successful. Animal studies suggested that treatment with lithium might be an alternative approach. Targets of lithium include paralogs of glycogen synthase kinase 3 (GSK3), and nonselective small-molecule inhibitors of these enzymes improved disease phenotypes in a fragile X syndrome mouse model. However, the potential therapeutic use of GSK3 inhibitors has been hampered by toxicity arising from inhibition of both α and β paralogs. Recently, we developed GSK3 inhibitors with sufficient paralog selectivity to avoid a known toxic consequence of dual inhibition, that is, increased β-catenin stabilization. We show here that inhibition of GSK3α, but not GSK3β, corrected aberrant protein synthesis, audiogenic seizures, and sensory cortex hyperexcitability in Fmr1-/y mice. Although inhibiting either paralog prevented induction of NMDA receptor–dependent long-term depression (LTD) in the hippocampus, only inhibition of GSK3α impaired mGluR5-dependent and protein synthesis–dependent LTD. Inhibition of GSK3α additionally corrected deficits in learning and memory in Fmr1-/y mice; unlike mGluR5 inhibitors, there was no evidence of tachyphylaxis or enhanced psychotomimetic-induced hyperlocomotion. GSK3α selective inhibitors may have potential as a therapeutic approach for treating fragile X syndrome. 2021-11-19T15:20:11Z 2021-11-19T15:20:11Z 2020 2021-11-19T15:14:10Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/138160 McCamphill, Patrick K, Stoppel, Laura J, Senter, Rebecca K, Lewis, Michael C, Heynen, Arnold J et al. 2020. "Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome." Science Translational Medicine, 12 (544). en 10.1126/SCITRANSLMED.AAM8572 Science Translational Medicine Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf American Association for the Advancement of Science (AAAS) PMC |
| spellingShingle | McCamphill, Patrick K Stoppel, Laura J Senter, Rebecca K Lewis, Michael C Heynen, Arnold J Stoppel, David C Sridhar, Vinay Collins, Katie A Shi, Xi Pan, Jen Q Madison, Jon Cottrell, Jeffrey R Huber, Kimberly M Scolnick, Edward M Holson, Edward B Wagner, Florence F Bear, Mark F Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome |
| title | Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome |
| title_full | Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome |
| title_fullStr | Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome |
| title_full_unstemmed | Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome |
| title_short | Selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile X syndrome |
| title_sort | selective inhibition of glycogen synthase kinase 3α corrects pathophysiology in a mouse model of fragile x syndrome |
| url | https://hdl.handle.net/1721.1/138160 |
| work_keys_str_mv | AT mccamphillpatrickk selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT stoppellauraj selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT senterrebeccak selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT lewismichaelc selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT heynenarnoldj selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT stoppeldavidc selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT sridharvinay selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT collinskatiea selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT shixi selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT panjenq selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT madisonjon selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT cottrelljeffreyr selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT huberkimberlym selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT scolnickedwardm selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT holsonedwardb selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT wagnerflorencef selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome AT bearmarkf selectiveinhibitionofglycogensynthasekinase3acorrectspathophysiologyinamousemodeloffragilexsyndrome |